Targeting AKT in HER2-Negative Breast Cancer: Implications for Future Clinical Practice

Review AKT as a therapeutic target in HER2-negative metastatic breast cancer and the potential of investigational AKT inhibitors in a focused text module, expert commentary, downloadable slideset, and infographic.

Share

Program Content

Activities

Targeting AKT in HER2-Negative BC
Targeting AKT in HER2-Negative Breast Cancer: Implications for Future Clinical Practice
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2023

Expires: July 26, 2024

Activities

Downloadable Slideset
Targeting AKT in HER2-Negative Breast Cancer: Implications for Future Clinical Practice
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2023

Activities

AKT Inhibitors in MBC
My Thoughts on the Potential of AKT Inhibitors in Metastatic Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2023

Activities

Targeting AKT in Breast Cancer
Targeting AKT in Breast Cancer: Emerging Therapies
Video
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2023

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca